Introduction: The prevalence of Attention-Deficit/Hyperactivity Disorder (ADHD) has risen over the last two decades, with a corresponding increase in the cost of its medication. Drug utilization studies in South Africa focusing on ADHD are limited.Areas covered: The primary aim was to determine the cost of methylphenidate and atomoxetine (used for ADHD). The Intercontinental Marketing Service (IMS) database which contains data of the private healthcare sector was interrogated from 2013 to 2016 (48-month period) focussing on methylphenidate and atomoxetine. Drug consumption was expressed in number of DDDs, DDDs/1000 inhabitants/day and cost in Rands.Expert opinion: Methylphenidate-containing products constituted a considerably higher percentage of the market share when compared to atomoxetine (90.30% versus 9.70%). The DDD/1000 inhabitants/day for methylphenidate was 6.010 with an annual cost for R266 691 778 in 2013, which increased to 7.827 DDDs/1000 inhabitants/day with an annual cost of R436 041 506 in 2016. Consumption of both methylphenidate and atomoxetine increased from 2013 to 2016. There was a preference for long-acting extended-release methylphenidate tablets even though the unit costs were higher when compared to the short-acting formulations. Despite increases in unit costs, the spend in South Africa showed an upward trend for methylphenidate and atomoxetine.

中文翻译：

---

南非私人医疗保健部门使用哌醋甲酯和托莫西汀治疗多动症的费用。

简介：在过去的二十年中，注意力缺乏/多动症（ADHD）的患病率上升，其药物成本也相应增加。南非针对ADHD的药物利用研究非常有限。研究范围：主要目的是确定哌醋甲酯和托莫西汀（用于ADHD）的成本。从2013年到2016年（48个月），对包含私人医疗保健部门数据的洲际市场营销服务（IMS）数据库进行了调查，重点是哌醋甲酯和阿莫西汀。药物消费以DDDs的数量，DDDs / 1000居民/天和以兰特表示的成本来表示。专家意见：含有哌醋甲酯的产品与阿托莫西汀相比占市场份额的百分比更高（90.30％对9.70％）。哌醋甲酯的每日DDD / 1000居民/天为6.010，2013年的年度成本为R266 691 778，2016年增至7.827 DDDs / 1000居民/天，年度成本为R436 041506。哌醋甲酯和托莫西汀的消费量均增加从2013年到2016年。尽管与短效制剂相比单位成本更高，但还是首选长效缓释哌醋甲酯片剂。尽管单位成本增加，但南非的哌醋甲酯和托莫西汀支出仍呈上升趋势。尽管与短效制剂相比单位成本更高，但还是首选长效缓释哌醋甲酯片剂。尽管单位成本增加，但南非的哌醋甲酯和托莫西汀支出仍呈上升趋势。尽管与短效制剂相比单位成本更高，但还是首选长效缓释哌醋甲酯片剂。尽管单位成本增加，但南非的哌醋甲酯和托莫西汀支出仍呈上升趋势。